CD47 has been found to be present on leukemic stem cells, but not on normal hematopoietic stem cells, offering an opportunity to target the source of the disease. Here, Irving Weissman, MD, of the Stanford University School of Medicine, Stanford, CA, discusses the use of an anti-CD47 antibody, which has shown promising results in combination with rituximab for follicular lymphoma and diffuse large B-cell lymphoma (NCT02953509). This interview was recorded at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland.
CD47-targeting antibody: targeting the source of non-Hodgkin lymphoma
